Abstract
As the principal active ingredient in the Chinese herb Tripterygium wilfordii Hook.F (TwHF), triptolide has been shown to have very strong antitumor properties. The trimethylation of lysine 4 on histone H3 (H3K4me3) has been proposed to promote gene expression, and the accumulation of H3K4me3 at the transcriptional start sites of oncogenes is involved in carcinogenesis. To identify the association between the reduction of H3K4me3 and the apoptosis of MM cells induced by triptolide, we investigated the global patterns of H3K4me3 occupancy in the MM cell genome. Combined analyses using ChIP-on-chip and western blotting showed that H3K4me3 were highly enriched on the gene promoters of c-Myc and VEGFA and were associated with the up-regulation of both genes. Treatment of KM3 cells with triptolide and siRNA targeting ASH2L reduced the expression of c-Myc and VEGFA. These results suggest that triptolide can down-regulate c-Myc and VEGFA expression by blocking the accumulation of H3K4me3 on their promoters,and thus play an important role in anti-MM mechanism.
Keywords: Apoptosis, ASH2L, c-Myc, H3K4me3, Multiple myeloma, Triptolide, VEGFA.
Current Pharmaceutical Biotechnology
Title:Triptolide Induces Cell Apoptosis by Targeting H3K4me3 and Downstream Effector Proteins in KM3 Multiple Myeloma Cells
Volume: 17 Issue: 2
Author(s): Lu Wen, Yan Chen, Ling L. Zeng, Fei Zhao, Sha Yi, Li J. Yang, Ben P. Zhang, Jie Zhao, Zi C. Zhao and Chun Zhang
Affiliation:
Keywords: Apoptosis, ASH2L, c-Myc, H3K4me3, Multiple myeloma, Triptolide, VEGFA.
Abstract: As the principal active ingredient in the Chinese herb Tripterygium wilfordii Hook.F (TwHF), triptolide has been shown to have very strong antitumor properties. The trimethylation of lysine 4 on histone H3 (H3K4me3) has been proposed to promote gene expression, and the accumulation of H3K4me3 at the transcriptional start sites of oncogenes is involved in carcinogenesis. To identify the association between the reduction of H3K4me3 and the apoptosis of MM cells induced by triptolide, we investigated the global patterns of H3K4me3 occupancy in the MM cell genome. Combined analyses using ChIP-on-chip and western blotting showed that H3K4me3 were highly enriched on the gene promoters of c-Myc and VEGFA and were associated with the up-regulation of both genes. Treatment of KM3 cells with triptolide and siRNA targeting ASH2L reduced the expression of c-Myc and VEGFA. These results suggest that triptolide can down-regulate c-Myc and VEGFA expression by blocking the accumulation of H3K4me3 on their promoters,and thus play an important role in anti-MM mechanism.
Export Options
About this article
Cite this article as:
Wen Lu, Chen Yan, Zeng L. Ling, Zhao Fei, Yi Sha, Yang J. Li, Zhang P. Ben, Zhao Jie, Zhao C. Zi and Zhang Chun, Triptolide Induces Cell Apoptosis by Targeting H3K4me3 and Downstream Effector Proteins in KM3 Multiple Myeloma Cells, Current Pharmaceutical Biotechnology 2016; 17 (2) . https://dx.doi.org/10.2174/1389201016666150930115555
DOI https://dx.doi.org/10.2174/1389201016666150930115555 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanism of Anti-Tumor Effect by Curcumin in Hematological Malignancies
Current Pharmaceutical Analysis MMPs in Ovarian Cancer as Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties
Protein & Peptide Letters Unexpected High Levels of Vorinostat when Combined with Vinorelbine in Patients with Advanced Cancer
Current Clinical Pharmacology A High-throughput Screening of a Chemical Compound Library in Ovarian Cancer Stem Cells
Combinatorial Chemistry & High Throughput Screening The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.
Current Pharmaceutical Biotechnology Diaryl Urea: A Privileged Structure in Anticancer Agents
Current Medicinal Chemistry Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry TRAIL: A Sword for Killing Tumors
Current Medicinal Chemistry Gene Expression-Based Pharmacodynamic Biomarkers: The Beginning of a New Era in Biomarker-Driven Anti-Tumor Drug Development
Current Molecular Medicine The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors
Mini-Reviews in Medicinal Chemistry High-Throughput Miniaturized Immunoassay for Human Interleukin-6 Using Electrochemical Sandwich-Type Enzyme Immunosensors
Current Pharmaceutical Analysis Radiopharmaceuticals Labelled with Copper Radionuclides: Clinical Results in Human Beings
Current Radiopharmaceuticals Pharmacokinetic Profiles of Anticancer Herbal Medicines in Humans and the Clinical Implications
Current Medicinal Chemistry Inhibition of Cyclin-Dependent Kinases - A Review of the Recent Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases
Current Drug Targets Effect and Mechanism of Curcumin on EZH2 - miR-101 Regulatory Feedback Loop in Multiple Myeloma
Current Pharmaceutical Design Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
Current Medicinal Chemistry